| Literature DB >> 31816866 |
Olympia Kouzi1, Eleni Pontiki1, Dimitra Hadjipavlou-Litina1.
Abstract
Indandiones are a relatively new group of compounds presenting a wide range of biological activities. The synthesis of these compounds was performed via a Knoevenagel reaction between anEntities:
Keywords: 2-arylidene-1,3-indandiones; Lipinski “Rule of five”; antioxidants; lipoxygenase inhibitors
Mesh:
Substances:
Year: 2019 PMID: 31816866 PMCID: PMC6930570 DOI: 10.3390/molecules24234411
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Scheme 1General synthesis of the new derivatives: 0.0068 mol of 1,3-indandione, 0.0075 mol of the corresponding arylaldehyde in 30 mL of absolute ethanol and piperidine 0.06 mL. Yields of the products are given in parentheses.
Molecular properties prediction-Lipinski “Rule of five”. Drug-likeness of the synthesized compounds.
| Compd. | milog | TPSA b | No Atoms | No O,N c | No OH, NH d | No Violations | No Rotational Bonds e | Volume f | MW g | logBBB h |
|---|---|---|---|---|---|---|---|---|---|---|
|
| 2.79 | 34.14 | 17 | 2 | 0 | 0 | 1 | 200.71 | 240.28 | 0.255 |
|
| 3.16 | 34.14 | 18 | 2 | 0 | 0 | 1 | 217.27 | 254.31 | 0.312 |
|
| 2.52 | 47.28 | 18 | 3 | 0 | 0 | 1 | 208.12 | 238.24 | 0.082 |
|
| 2.89 | 34.14 | 18 | 2 | 0 | 0 | 1 | 209.99 | 234.25 | 0.270 |
|
| 3.64 | 34.14 | 20 | 2 | 0 | 0 | 2 | 237.41 | 260.29 | 0.387 |
|
| 3.75 | 37.38 | 23 | 3 | 0 | 0 | 3 | 283.32 | 303.36 | 0.371 |
|
| 4.62 | 43.38 | 25 | 3 | 0 | 0 | 3 | 290.39 | 326.35 | 0.446 |
|
| 5.35 | 43.38 | 27 | 3 | 0 | 1 | 4 | 325.07 | 419.27 | 0.560 |
|
| 5.94 | 54.37 | 27 | 3 | 3 | 1 | 3 | 350.38 | 362.47 | 0.541 |
|
| 5.94 | 54.37 | 27 | 3 | 1 | 1 | 3 | 350.38 | 362.47 | 0.541 |
|
| 3.09 | 49.93 | 21 | 3 | 1 | 0 | 1 | 238.97 | 273.29 | 0.144 |
|
| 3.04 | 49.93 | 21 | 3 | 1 | 0 | 1 | 238.97 | 273.29 | 0.144 |
N Atoms denotes the number of atoms in the compound; a Logarithm of partition coefficient between-octanol and water (milogP); b Topological polar surface area (TPSA); c Number of hydrogen bond acceptors (n-ON); d Number of hydrogen bond donors (n-OHNH); e Number of rotatable bonds (n-rotb); f Molecular Volume; g Molecular Weight; h blood–brain barrier (logBBB = 0.155 logP − 0.01TPSA + 0.164) [57].
Lipophilicity values: experimental RM%. E Hydration Energy. E(HOMO). Interaction with the stable radical 1,1-diphenyl-picrylhydrazyl (DPPH), In vitro lipoxygenase (LOX) inhibitory activity at 100 µM.
| Compd. | RM a (±SD) b | E | E(HOMO) | RA% 50 µM | RA% 50 µM | RA% 100 µM | RA% 100 µM | RA% 200 µM | RA% 200 µM | LOX |
|---|---|---|---|---|---|---|---|---|---|---|
|
| 0.031 ± 0 | −20.48 | −0.310777 | 2 | 0 | 16 | 16 | 2 | 6 | 32.6 |
|
| 0.031 ± 0 | −17.37 | −0.309938 | 2 | 2 | 16 | 16 | 4 | 7 | 45 |
|
| 0.014 ± 0 | −7.67 | 0.291110 | 20 | 23 | 37 | 40 | 61 | 75 | 35.7 |
|
| −0.615 ± 0.02 | −6.53 | −0.306356 | 5 | 10 | 26 | 32 | 23 | 32 | 35 |
|
| 0.158 ± 0 | −6.71 | −0.302600 | 21 | 25 | 44 | 48 | 57 | 72 | 26.4 |
|
| −0.527 ± 0 | −9.86 | −0.271983 | 6 | 6 | 22 | 23 | 15 | 18 | 17.7 |
|
| −0.196 ± 0.02 | −7.30 | −0.303773 | 27 | 35 | 40 | 50 | 75 | 85 | 67.3 |
|
| * | −9.31 | −0.314300 | 4 | 5 | 7 | 7 | 0 | 0 | 3.6 |
|
| −1.038 ± 0 | −5.68 | −0.306356 | 4 | 3 | 3 | 1 | 6 | 6 | no |
|
| −0.103 ± 0 | −5.71 | −0.314300 | 13 | 17 | 100 | 85 | 71 | 71 | no |
|
| −0.196 ± 0.02 | −12.71 | −0.279993 | 2 | 2 | 19 | 19 | 10 | 10 | 38.6 |
|
| −0.134 ± 0.02 | −12.72 | −0.279598 | 3 | 3 | 17 | 17 | 4 | 6 | 58.9 |
|
| - | 81 | 83 | 87 | 93 | 94 | 96 | 93 |
a RM values are the average of at least 5 measurements, b SD standard deviation < 10%; * could not be measured under the reported experimental conditions.
% Anti-lipid peroxidation (AAPH), Decolorization activity ABTS+·% assays. In vitro inhibition of trypsin induced proteolysis (% Trypsin Inh -Iptr%), thrombin inhibition TH%, In vivoanti-inflammatory activity (CPE %).
| Compd. | AAPH% 100 µΜ | ABTS +. % 100 µΜ | Iptr% 100 µΜ | TH% 100 µΜ | CPE a % |
|---|---|---|---|---|---|
|
| 90 | 9 | no | no | 57 ** |
|
| 92 | 2 | no | - | 45 * |
|
| no | 20 | 17 | 39 | 50 * |
|
| no | 19 | 4 | no | 28 * |
|
| no | no | no | - | - |
|
| 9 | 22 | 29 | 19 | - |
|
| 82 | 37 | 33 | no | 41 ** |
|
| 79 | 16 | 85 | 100 | 46 * |
|
| 96 | no | 98 | 0 | - |
|
| 85 | 39 | no | 27 | 42 * |
|
| no | 8 | 6 | - | - |
|
| 31 | no | no | - | 42 ** |
|
| 93 | 91 | |||
|
| 47 | ||||
|
| 54 | ||||
|
| 98 |
* p < 0.01, ** p < 0.05. a % of reduction of the rat paw edema (CPE %) induced by carrageenin at the dose of 0.01 mmol/Kg/body weight.no: no action under the experimental conditions.
Figure 1Preferred docking pose of 7(depicted in blue) bound to soybean lipoxygenase (LOX-1).
Comparison table with multi-target pleiotropic compounds.
| Compd. | % LOX Inh. 100 μM | % IPr 100 μΜ | % TH 100 μΜ | AAPH% 100 μM | % CPE |
|---|---|---|---|---|---|
|
| 67.3 | 82 | 41 | ||
|
| 85 | 100 | 79 | 46 | |
|
| 98 | 96 |